<DOC>
	<DOCNO>NCT03028740</DOCNO>
	<brief_summary>The STELLARIS study conduct confirm efficacy safety cenicriviroc ( CVC ) treatment liver fibrosis adult subject NASH .</brief_summary>
	<brief_title>STELLARIS : Phase 3 Study Efficacy Safety CVC Treatment Liver Fibrosis Adults With NASH</brief_title>
	<detailed_description>The STELLARIS study conduct 2 part . Part 1 examine surrogate endpoint improvement fibrosis least 1 stage ( nonalcoholic steatohepatitis clinical research network [ NASH CRN ] ) worsen steatohepatitis Month 12 . Subjects Part 1 continue Part 2 additional subject newly randomize Part 2 determine long-term clinical outcome compose histopathologic progression cirrhosis , liver-related clinical outcome , all-cause mortality .</detailed_description>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<mesh_term>TAK-652</mesh_term>
	<criteria>1 . Male female subject age 1875 year 2 . Ability understand sign write informed consent form ( ICF ) 3 . Histological evidence NASH base central read Screening biopsy 4 . Histological evidence Stage 2 3 liver fibrosis per NASH CRN System base central read Screening biopsy slide 5 . Females childbearing potential male participate study must agree use least 2 approve method contraception throughout duration study 30 day stop study drug . Females postmenopausal must documentation cessation menses ≥ 12 month serum folliclestimulating hormone ( FSH ) ≥ 30 mU/mL Screening . 1 . Inability undergo liver biopsy 2 . Hepatitis B surface antigen ( HBsAg ) positive 3 . Hepatitis C antibody ( HCVAb ) positive 4 . Human immunodeficiency virus ( HIV ) 1 HIV2 infection 5 . Prior plan liver transplantation 6 . Other known cause chronic liver disease 7 . History presence cirrhosis and/or hepatic decompensation include ascites , hepatic encephalopathy variceal bleed 8 . Alcohol consumption great 21 units/week male 14 units/week female 9 . AST &gt; 200 IU/L male females Screening 10 . ALT &gt; 250 IU/L male &gt; 200 IU/L female Screening 11 . HbA1c &gt; 10 % Screening 12 . Serum albumin &lt; 3.5 g/dL 13 . Estimated glomerular filtration rate ( eGFR ) &lt; 50 mL/min/1.73 m2 accord Modification Diet Renal Disease ( MDRD ) equation 14 . Platelet count &lt; 100,000/mm3 15 . Total bilirubin &gt; 1.5 mg/dL 16. International normalize ratio ( INR ) &gt; 1.3 17 . Model end stage liver disease ( MELD ) score &gt; 12 18 . Weight reduction bariatric surgery past 5 year plan conduct study ( include gastric banding ) 19 . History malignancy within past 5 year ongoing malignancy basal cell carcinoma , resect noninvasive cutaneous squamous cell carcinoma 20 . Active , serious infection require parenteral antibiotic antifungal therapy within 30 day prior Screening Visit 21 . Clinically significant cardiovascular cerebrovascular disease within past 3 month 22 . Females pregnant breastfeed 23 . Current anticipate treatment radiation therapy , cytotoxic chemotherapeutic agent immunomodulating agent 24 . Receiving glucagonlike peptide 1 ( GLP1 ) receptor agonist , dipeptidyl peptidase 4 ( DPP4 ) inhibitor , sodiumglucose cotransporter 2 ( SGLT2 ) inhibitor , thiazolidinedione ( TZD ) less 6 month stable therapy prior Screening liver biopsy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>